Last updated: 20 August 2024 at 6:06pm EST

David Drutz Net Worth




The estimated Net Worth of David Drutz is at least $457 Thousand dollars as of 19 August 2024. David Drutz owns over 41,750 units of Altimmune Inc stock worth over $456,786 and over the last 7 years he sold ALT stock worth over $0. In addition, he makes $0 as Independent Director at Altimmune Inc.

David Drutz ALT stock SEC Form 4 insiders trading

David has made over 12 trades of the Altimmune Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 41,750 units of ALT stock worth $106,463 on 19 August 2024.

The largest trade he's ever made was exercising 41,750 units of Altimmune Inc stock on 19 August 2024 worth over $106,463. On average, David trades about 4,241 units every 134 days since 2017. As of 19 August 2024 he still owns at least 63,708 units of Altimmune Inc stock.

You can see the complete history of David Drutz stock trades at the bottom of the page.





David Drutz biography

Dr. David J. Drutz M.D. serves as Independent Director of the Company. Dr. Drutz is the President of Pacific Biopharma Associates, a biopharmaceutical consulting company that he founded in 1999. From 2008-2015, he served variously as Director, CEO, Executive Chairman and Chief Medical Officer of DARA BioSciences (NASDAQ:DARA), an oncology supportive care company located in Raleigh, NC. He served previously as Chairman of Tranzyme (NASDAQ:TZYM; 2000-2010); and Director of MethylGene (TSX:MYG; 2000-2010) and Gentris Corporation (2007-2014). From 1999-2008 he was a general partner with Pacific Rim Ventures, a Tokyo-based venture capital firm. Dr. Drutz’s management experience includes tenures as VP Biological Sciences and VP Clinical Research at Smith Kline & French Laboratories; VP Clinical Development at Daiichi Pharmaceutical Corporation; and CEO of Inspire Pharmaceuticals (1995-1998) and Sennes Drug Innovations (1994-1995). Earlier, Dr. Drutz was Professor of Medicine, Chief of the Division of Infectious Diseases, and the founder of the NSF Center for Cell Regulation at the UT Health Science Center, San Antonio. Dr. Drutz received his M.D. from the University of Louisville School of Medicine and postgraduate training in internal medicine and infectious diseases at Vanderbilt University School of Medicine, serving subsequently as a research medical officer in the U.S. Navy (LCDR, SNR). He is certified by the American Board of Internal Medicine; a fellow of the American College of Physicians and the Infectious Diseases Society of America; a member of Alpha Omega Alpha, the American Society of Clinical Oncology and the American Society for Clinical Investigation; and the author of more than 200 peer-reviewed publications in the area of infectious diseases. Dr. Drutz brings significant experience in biotechnology investment and as a physician to Altimmune’s board of directors.



How old is David Drutz?

David Drutz is 81, he's been the Independent Director of Altimmune Inc since 2018. There are no older and 14 younger executives at Altimmune Inc.

What's David Drutz's mailing address?

David's mailing address filed with the SEC is C/O ALTIMMUNE, INC., 910 CLOPPER ROAD,, SUITE 201S, GAITHERSBURG, MD, 20878.

Insiders trading at Altimmune Inc

Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners..., and Mitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.



What does Altimmune Inc do?

altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current



What does Altimmune Inc's logo look like?

Altimmune Inc logo

Complete history of David Drutz stock trades at Altimmune Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
19 Aug 2024 David Drutz
Director
Option 41,750 $2.55 $106,463
19 Aug 2024
63,708
15 Aug 2023 David Drutz
Director
Buy 300 $2.88 $864
15 Aug 2023
29,785
23 Mar 2023 David Drutz
Director
Buy 9,000 $4.27 $38,430
23 Mar 2023
29,484
18 Nov 2022 David Drutz
Director
Option 139 $2.40 $334
18 Nov 2022
20,151
15 Jun 2022 David Drutz
Director
Buy 1,000 $8.00 $8,000
15 Jun 2022
20,012
24 May 2022 David Drutz
Director
Buy 1,200 $4.50 $5,400
24 May 2022
19,012
25 Jan 2022 David Drutz
Director
Option 70 $2.40 $168
25 Jan 2022
17,882
14 Dec 2021 David Drutz
Director
Option 139 $2.40 $334
14 Dec 2021
17,812
19 Nov 2021 David Drutz
Director
Option 70 $2.40 $168
19 Nov 2021
17,673
13 Nov 2020 David Drutz
Director
Option 60 $2.40 $144
13 Nov 2020
17,603
24 Sep 2020 David Drutz
Director
Option 16,850 $12.03 $202,706
24 Sep 2020
17,543
22 Aug 2017 David Drutz
Director
Buy 10,000 $2.21 $22,100
22 Aug 2017
30,777


Altimmune Inc executives and stock owners

Altimmune Inc executives and other stock owners filed with the SEC include: